KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
暂无分享,去创建一个
David M. Wilson | P. Hoff | S. Dearden | G. McWalter | S. Morgan | J. Jürgensmeier | J. Robertson | L. Brooks | John C Smith | J. Jürgensmeier